AstraZenca is testing a once-daily PCSK9 inhibitor, currently known as AZD0780. After 12 weeks of use alongside standard ...

A class action lawsuit was filed against Merck & Co. (MRK) by Levi & Korsinsky on February 12, 2025. The plaintiffs ...

Merck & Co. Inc. closed 41.19% below its 52-week high of $134.63, which the company reached on June 25th.

We recently published a list of 10 Best Medical Stocks to Buy According to Billionaires. In this article, we are going to ...

Leaders at Merck & Co. Inc. are facing a new derivative shareholder lawsuit over allegations that they made misleading ...

The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck se ...

We came across a bullish thesis on Merck & Co., Inc. (MRK) on Substack by Charly AI. In this article, we will summarize the ...

Daily Merck & Company, Inc. Dow pharmaceutical components are leading overall index losses. Merck emerged as the biggest decliner, down 4.6%, while Amgen shed 4.3% and Johnson & Johnson lost 4.1%.

The Dow Jones Industrial Average is declining Wednesday morning with shares of Amgen and Merck seeing the biggest losses for the price-weighted average.

Merck (NYSE:MRK) recently presented promising results from the Phase 3 ZENITH trial for its drug WINREVAIR, but the company's stock performance over the past month tells a different story ...

Semarion's SemaCyte® technology transforms adherent cell assays, enabling faster, automated workflows that enhance ...